Ulrich Jaeger

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

Timothy J. McDonnell, Natasha G. Deane, Frances M. Platt et al. · Cell · 1989 · 1.2K citations

Life Sciences, Cell Biology, Immunology +13

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper et al. · The Lancet Oncology · 2011 · 811 citations

Medicine, Oncology, Pharmacotherapy +13